Milestone Scientific Corp (MLSS) - Forward Price-to-Revenue Multiple
Milestone Scientific (MLSS) is battling clinic conservatism and the dominance of budget syringes. The forward price-to-sales ratio helps assess the asset's price volatility, where 2.70 represents the current metric level. Business resilience relies on recurring sales of disposable tips, while growth potential is driven by EU expansion and the implementation of Wand/STA systems in dentistry.
Milestone Scientific Corporation - analytical breakdowns and key metrics (MLSS)
- market price and analyst price targets:
- market capitalization indicators:
- business book valuation details:
- issuer credit burden and liquidity indicators:
Debt to Equity Milestone Scientific|MLSS - Long-Term Debt to Capital Ratio|Short-Term Debt to Equity Ratio Milestone Scientific|MLSS - Company Cumulative Indebtedness|Debt to Book Capitalization Ratio Milestone Scientific Corporation|MLSS - Long-Term Debt Volume|Company Short-Term Debt Milestone Scientific|Quick Ratio milestonescientific.com
- business earnings and investment ratios data:
MLSS - Net Financial Result|Expected Profit Milestone Scientific|MLSS - Price to Earnings Ratio|Forward P/E Multiple Milestone Scientific Corp|MLSS - Price to Earnings Adjusted for Growth Rate|Enterprise Value to Earnings Before Interest, Taxes, Depreciation and Amortization Milestone Scientific Corporation|MLSS - Operating income before deduction of amortization|Net earnings per share for the last 12 months Milestone Scientific|MLSS - Earnings per share for the last four quarters|Year-over-year earnings per share growth for the last twelve months milestonescientific.com|MLSS - Earnings per share growth rate in current year|Net earnings per share growth forecast for next year Milestone Scientific
- sales and revenue data:
General company analysis:MLSS (Milestone Scientific Inc.)
The forward P/S ratio assesses the market value of a business relative to expected revenue, allowing for a determination of the premium paid for sales growth potential. By analyzing the forward P/S of Milestone Scientific (MLSS), an investor can diagnose the adequacy of the asset's price, taking into account the risks associated with outsourcing serial production and the critical dependence on the quality of third-party contract vendors.
Analysis of competing companies
Price-to-Projected Revenue Ratio Intuitive ISRG|Forward Price to Sales DHR|BDX: Forward Price-to-Revenue Multiple|STE - Forward P/S Multiple|West Pharmaceutical Services (WST) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple baxter.com|MASI (Masimo) - Forward P/S Multiple|Market Cap to Future Revenue Ratio Stevanato Group SpA STVN|Price-to-Projected Revenue Ratio Teleflex Inc (TFX)|Merit Medical Corp - Market Cap to Projected Revenue|Envista Holdings - Forward Price-to-Revenue Multiple|Price to Expected Revenue Ratio ICUI (icumed.com)|XRAY - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio LeMaitre Vascular Inc LMAT|AtriCure Corp (ATRC) - Price-to-Projected Revenue Ratio|Forward Price-to-Revenue Multiple STAAR Surgical Co|NAGE (ChromaDex Corporation) - Forward P/S Multiple|zimvie.com (ZIMV) - Market Cap to Expected Sales Ratio|Price-to-Projected Revenue Ratio AngioDynamics (ANGO)|Price-to-Projected Revenue Ratio CERS (Cerus Corp.)|Forward P/S Multiple TKNO (Alpha Teknova Inc)|Monogram Orthopedics Inc. (MGRM) - Market Cap to Future Revenue Ratio|STSS - Price-to-Projected Revenue Ratio|Market Cap to Expected Sales Ratio InfuSystem Holdings INFU|UTMD (Utah Medical Products, Inc.) - Forward Price-to-Revenue Multiple|KRMD: Price to Expected Revenue Ratio|Price-to-Projected Revenue Ratio Nyxoah, S.A.|Market Cap to Future Revenue Ratio Microbot Medical, Inc MBOT|Price-to-Projected Revenue Ratio Pro-Dex, Inc. (PDEX)|zentek.com - Market Cap to Projected Revenue|Forward P/S Multiple ELUT (Elutia)|NEXGEL Inc. (NXGL) - Market Cap to Future Revenue Ratio|RVP: Forward Price-to-Revenue Multiple|Forward Price to Sales HBIO (harvardbioscience.com)|Femasys Inc. (FEMY) - Price-to-Projected Revenue Ratio|MHUA - Market Cap to Expected Sales Ratio|POAI (Predictive Oncology Inc) - Forward P/S Multiple|Forward Price-to-Revenue Multiple Callan JMB Corp (CJMB)|Forward P/S Multiple ATRI|Market Cap to Expected Sales Ratio NeuroMetrix Corporation
